Secondary analysis of the phase 3 PROpel trial (796 patients with mCRPC): adding olaparib to abiraterone did not change health-related quality of life (FACT-P) or pain scores (BPI-SF) versus placebo plus abiraterone.
Secondary analysisn = 796
Armstrong et al. Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study